A retrospective cost-effectiveness analysis of the treatment of onychomycosis in general practice

British Journal of Dermatology

Volumn 139, Issue 4, 1998, Pages 660-664

  Humphrey, K M ^a   Cork, M J ^b   Haycox, A ^c  

^a Decision Resources Group   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; GRISEOFULVIN; TERBINAFINE; TIOCONAZOLE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; DRUG UTILIZATION; GENERAL PRACTICE; HUMAN; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; COST-BENEFIT ANALYSIS; ENGLAND; FAMILY PRACTICE; GRISEOFULVIN; HUMANS; IMIDAZOLES; MORPHOLINES; NAPHTHALENES; ONYCHOMYCOSIS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES;

EID: 0031692118     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1998.02463.x     Document Type: Article

References (8)

1. Roberts DT. Prevalence of dermalophyte infections in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992; 126 (Suppl. 39): 23-37.
2. Goodfield MJD, Bosanquet N, Evans EGV et al. Cost effective clinical management of onychomycosis. Br J Med Econ 1994; 7: 15-23.
3. Anonymous. Antifungal drugs (editorial). Q J Med 1995; 88: 681-4.
4. Arikian SR, Einarson TR, Kobelt-Nguyen G et al. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. Br J Dermatol 1994: 130 (Suppl. 43): 35-44.
5. Zaug M. Amorolfine nail lacquer: once-weekly application in onychomycosis. JAMA 1993; 9 (Suppl. 4): 19-22.
6. Hay RJ, Mackie RM, Clayton YM et al. Tioconazole nail solution - an open study of its efficacy in general practice. Clin Exp Dermatol 1985; 10: 111-15.
7. Davis R, Balfour JA. Focus on terbinafine. Pharmacoeconomics 1995; 8: 253-69.
8. Baran R, Belaich S, Beylot J et al. Comparative multi-centre double-blind study of terbinafine (250 mg/day) versus griseofulvin (1 g per day) in the treatment of dermatophyte onychomycosis. J Dermatol Treat 1997; 8: 93-7.